TNFRSF17 and neoplasm: These findings highlight the potential to fine‐tune therapeutic efficacy by adjusting the dosing ratio or administration sequence of Fab’CD3‐MORF2 and Fab’BCMA‐MORF1, allowing for more precise control of T cell activation and tumor specificity.